{"entity":{"id":"paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019","kind":"paper","name":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","aka":[],"tldr":"The largest Chinese triple-negative cohort, 465 patients from Fudan, carried more PIK3CA mutations than American tumours and sorted into four subtypes, with the luminal androgen receptor type showing HER2 mutations and CDKN2A loss.","summary":"Clinical, genomic and transcriptomic data of 465 primary TNBCs were analysed. PIK3CA mutations and copy-number gains of chromosome 22q11 were more frequent in the Chinese cohort than in The Cancer Genome Atlas. TNBCs were classified into four transcriptome-based subtypes: luminal androgen receptor (LAR), immunomodulatory, basal-like immune-suppressed and mesenchymal-like, with putative therapeutic targets or biomarkers identified in each. The LAR subtype showed more ERBB2 somatic mutations, infrequent mutational signature 3 and frequent CDKN2A loss.","asOf":"2026-09-24","links":[{"label":"Jiang et al., Cancer Cell 2019: genomic and transcriptomic landscape of 465 Chinese TNBCs (FUSCC)","url":"https://doi.org/10.1016/j.ccell.2019.02.001"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/30853353/"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":["pik3ca","her2","cdkn2a","androgen-receptor"],"drugs":[],"companies":[],"institutions":["zhongshan-hospital-fudan"],"pathways":[],"terms":["mutational-signature"],"trials":[],"people":["jiang-yi-zhou","shao-zhi-ming"],"bottlenecks":[],"keyPapers":[],"journals":["cancer-cell"],"dependsOn":[],"notes":[],"journal":"Cancer Cell","year":2019,"doi":"10.1016/j.ccell.2019.02.001","pmid":"30853353","authors":"Jiang YZ, Ma D, Suo C, et al.","paperType":"translational","findings":["PIK3CA mutations and 22q11 gains more frequent than in TCGA.","Four subtypes: LAR, immunomodulatory, basal-like immune-suppressed, mesenchymal-like.","LAR: more ERBB2 mutations, infrequent signature 3, frequent CDKN2A loss."],"whatItMeans":"The FUSCC cohort is the East Asian reference and the basis of the FUTURE subtype-guided umbrella trial; its LAR findings point to CDK4/6 and HER2-mutant strategies rather than PARP inhibitors for that subtype.","caveats":["Single-institution Chinese cohort; subtype frequencies are not in the abstract and are not quoted here.","Comparison with TCGA mixes sequencing platforms."],"changedPractice":false,"participants":465},"route":"/key-papers/paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"},{"id":"cdkn2a","kind":"target","name":"CDKN2A","route":"/targets/cdkn2a/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/"}],"institution":[{"id":"zhongshan-hospital-fudan","kind":"institution","name":"Zhongshan Hospital, Fudan University","route":"/institutions/zhongshan-hospital-fudan/"}],"term":[{"id":"mutational-signature","kind":"term","name":"Mutational signature","route":"/terms/mutational-signature/"}],"person":[{"id":"jiang-yi-zhou","kind":"person","name":"Yi-Zhou Jiang","route":"/people/jiang-yi-zhou/"},{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","route":"/people/shao-zhi-ming/"}],"journal":[{"id":"cancer-cell","kind":"journal","name":"Cancer Cell","route":"/journals/cancer-cell/"}]}}